NCT00001056View on ClinicalTrials.gov

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1994

Conditions
HIV Infections
Interventions
BIOLOGICAL

gp160 Vaccine (Immuno-AG)

Trial Locations (3)

14642

Univ. of Rochester AVEG, Rochester

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

63104

St. Louis Univ. School of Medicine AVEG, St Louis

Sponsors

Collaborators (1)

Immuno-US
All Listed Sponsors
collaborator

Immuno-US

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH